Back to top

Analyst Blog

Nerve testing devices maker NeuroMetrix has commenced the commercial shipments of its NC-stat DPNCheck test. The company launched the test at the annual conference of the American Diabetes Association (“ADA”) in San Diego, California, in July 2011.

The Massachusetts-based company noted that the NC-stat DPNCheck has been shipped primarily to endocrinologists and podiatrists who have chosen a thirty-day product evaluation to review its role in diabetes management. NeuroMetrix has also provided product training and support, which is being offered by its eight-person specialty sales team.

The NC-stat DPNCheck test has been designed for evaluating systemic neuropathies such as diabetic peripheral neuropathy (“DPN”), a common and serious complication of diabetes, affects roughly 60%-70% of diabetics and may lead to foot ulcers and amputations. It is a modified version of NeuroMetrix’s popular NC-stat device for detecting DPN.

NC-stat DPNCheck is geared for the early detection, confirmation, and monitoring of DPN in a cost-effective manner at the point-of-care, thereby enabling NeuroMetrix to address the unmet need for a widely available, standardized test for this condition.

NeuroMetrix develops and markets devices that help physicians detect and treat diseases and peripheral nerve injuries, and offer regional anesthesia and pain control. The company’s principal products are ADVANCE and NC-stat devices for nerve conduction study (“NCS”). NeuroMetrix competes with Medtronic (MDT - Analyst Report) among others.

NeuroMetrix, in January 2011, modified its operational focus in favor of diabetes, in particular the diagnosis and monitoring of DPN. Moreover, the company, in March 2011, established a scientific advisory board for its DPN test. The board consists of eminent international experts who are working closely with the company for improving detection, monitoring and management of DPN.

Please login to Zacks.com or register to post a comment.